Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 69   

Articles published

ARNA 3.92 -0.06 (-1.51%)
price chart
Important Insights For Arena Pharmaceuticals
As a long time Arena Pharmaceuticals (NASDAQ:ARNA) bull, it is rewarding to begin to see updates from the company that detail the future for the franchise and how it mirrors many of my thoughts as to what the underlying opportunity could be. On this ...
Arena Pharma Sinks Under Weight Of Vivus' Troubles
VIVUS Shares Hit Hard after Earnings
The other two in this high profile category include: Orexigen Therapeutics (NASDAQ: OREX) and Arena Pharmaceuticals (NASDAQ: ARNA). VIVUS appears to be very much a small cap company after reporting a revenue of only $40,000 which is way below ...
Vivus Or Arena: Who Has The Edge?  Seeking Alpha
Vivus Weight-Loss Drug Launch In Early Trouble
South Korea's Ildong Pharma To License Arena Pharma Drug
29, 2012) - U.S.-based Arena Pharmaceuticals, Inc. has licensed its internally discovered thrombosis drug, temanogrel, to Seoul, Korea-based Ildong Pharmaceutical Co.
Arena Pharma Is Still A Good Short
My advice to lorcaserin bulls would be to cherish the moment but sell the stock...This is as good as it gets. If you're one of the lucky few that can find shares to borrow, congrats -- you've got a good short.
Vivus, Arena shares jump on insurance coverage for diet pills
N) said it would provide coverage for diet pills of Vivus Inc (VVUS.O) and Arena Pharmaceuticals Inc (ARNA.O), sending the obesity drugmakers' shares up.
Vivus Jumps on Aetna Qsymia Ruling: San Francisco Mover  Bloomberg
Vivus, Arena, Orexigen Get a Bounce After Aetna Says It Will Cover Diet Pills
Indian board rejects AstraZeneca's patent plea on cancer drug
Natco and another domestic drugmaker, G. M. Pharma, had opposed the initial patent application for AstraZeneca quinazoline derivative.
Amgen Therapy Slims Monkeys as Study Seeks Obesity Drug
The Food and Drug Administration this year approved its first new obesity drugs, Vivus Inc.'s Qsymia and Arena Pharmaceuticals Inc.'s Belviq, since Roche Holding AG's Xenical in 1999. Diabetes, caused by the body's inability to sufficiently produce the ...
FSD Drugs Advance as Women Push for Equal Access
In July, investors raised $20 million for startup Sprout Pharmaceuticals, which hopes to succeed where Boehringer Ingelheim failed by bringing flibanserin through development phases to market.
Short Interest Swings in Biotech Stocks (AMGN, BIIB, VRTX)
Shares sold short in Arena Pharmaceuticals (NASDAQ: ARNA), Dendreon (NASDAQ: DNDN), Gilead Sciences (NASDAQ: GILD), Illumina (NASDAQ: ILMN) and VIVUS (NASDAQ: VVUS) grew somewhat between the October 15 and October 31 settlement dates.
Prescription drug deaths: Two stories
Pete Jackson attended his brother-in-law's funeral along with his daughter, Emily, six years ago. He never dreamed it would be the last day of his daughter's life.